Announcements Trials

Browse Landscape

Phase

Phase NA 26 Phase 3 1 Phase 2 1 Phase 1 1

Status

Sponsor Class

INDUSTRY 2 OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 1 Heart Diseases 1

Interventions

Cisplatin 1038 Cyclophosphamide 972 Carboplatin 952 Radiotherapy 890 Bevacizumab 845 Gemcitabine 817 pembrolizumab 758 Paclitaxel 738 Docetaxel 733 Oxaliplatin 704 Capecitabine 646 Fluorouracil 563 Rituximab 559 Nivolumab 506 Dexamethasone 487 Etoposide 468 Doxorubicin 458 Irinotecan 442 Drug Therapy 400 Leucovorin 376 Cytarabine 342 Cetuximab 338 Lenalidomide 326 Trastuzumab 321 Pemetrexed 314 durvalumab 295 Filgrastim 287 Magnetic Resonance Spectroscopy 277 Temozolomide 275 Prednisone 273

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × OTHER × Mass Screening × Clear all

NCT01714271 2023-10-02

Promotora-based Latino Family CVD Risk Reduction

University of California, Los Angeles

Phase 2 Completed

Heart Diseases, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡